Abstract: There is disclosed a combination oral dosage form pharmaceutical composition comprising a bitter receptor agonist and a gut-signaling compound. i.e., a gut-signaling peptide analog and/or gut-signaling hormone enhancer. And there is disclosed a method for treating obesity, diabetes, metabolic syndrome, glycemic control hyperlipidemia, and effecting weight loss comprising administering an effective amount of a pharmaceutical composition comprising a bitter receptor agonist and a gut-signaling compound, i.e., a gut-signaling peptide analog and/or gut-signaling hormone enhancer, as described above and herein.

Abstract: There is disclosed a pharmaceutical composition comprising a bitter receptor agonist comprising a denatonium salt, wherein the denatonium salt is selected from the group consisting of denatonium acetate (DA), denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate, for use in a method for preventing, preventing progression and/or treating a fatty liver disease. In some embodiments, the daily dose of the denatonium salt for preventing or preventing progression of a fatty liver disease is from 25 mg/kg to 45 mg/kg QD and the daily dose of the denatonium salt for treating an existing fatty liver disease is from 70 mg/kg to 200 mg/kg per day administered QD or BID.

Abstract: There is disclosed a method for treatment, prevention, and/or slowing of progression for various chronic inflammatory disorder groups including (1) type 2 diabetes group (metabolic syndrome (MET), obesity, hyperglycemia); (2) ARDS (acute respiratory distress syndrome); (3) chronic autoimmune inflammatory disorders (rheumatoid arthritis (RA), lupus, and psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolome-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) hyperphagia disorders such as Prader-Willi Syndrome and other monogenic and syndromic obesity disorders including leptin pathway deficiencies, each comprising administering orally a pharmaceutical composition comprising a denatonium salt.

Abstract: Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm.

Abstract: There is disclosed a method for treatment, prevention, and/or slowing of progression for various chronic inflammatory disorder groups including (1) type 2 diabetes group (metabolic syndrome (MET), obesity, hyperglycemia); (2) ARDS (acute respiratory distress syndrome); (3) chronic autoimmune inflammatory disorders (rheumatoid arthritis (RA), lupus, and psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolome-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) hyperphagia disorders such as Prader-Willi Syndrome and other monogenic and syndromic obesity disorders including leptin pathway deficiencies, each comprising administering orally a pharmaceutical composition comprising a denatonium salt.

Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.

Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.

Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.

Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.